Press RELEASE April, 20 2021

FOR IMMEDIATE RELEASE WASHINGTON D.C.

Contact: Ken Grubbs April 20, 2021

202-349-9650 ext. 800

American Council of Cannabis Medicine Announces Landmark Memorandum of Understanding Between Industry Leaders

Washington, DC — The American Council of Cannabis Medicine (ACCM) announced a memorandum of understanding (MOU) with multiple cannabis-industry stakeholders that will increase collaboration in areas of mutual interest and allow the industry and legislators to gain a deeper understanding of and support for U.S. medical cannabis and its impact on the diverse stakeholder community represented. The current and pressing objective is to facilitate legislation that advances medical cannabis at the federal level.

“As a practicing physician for nearly 40 years, it’s exciting to see the tremendous progress being made when it comes to bona-fide healthcare uses for cannabis,” said Jeffrey S. Block, M.D. Dr. Block is an American physician, botanist, cannabinoid-medicine thought leader, and ASCM Board of Regents member. “This memorandum of understanding represents a significant step forward in advancing medical access and clinical research.”

Narith Panh, Chief Strategy Officer for Dragonfly Wellness (Utah) and ACCM Cannabis Industry Liaison Committee Member recently stated, “As a vertically integrated company, we operate cultivation facilities, extraction and processing facilities, and retail pharmacy, so we understand all aspects of the industry. Our overall commitment is to help as many medical cannabis patients in the most ethical, professional, and affordable way. That's why we have aligned with ACCM. As the voice of the Medical Cannabis Industry, ACCM shares our vision and values. We are pleased to support the Alliance and join in the MOU as an active participant.”

The MOU formalizes relationships established over the last few years and was officially announced at ACCM’s Stakeholder Alliance final meeting April 19, 2021. MOU signatories will actively participate in the Alliance—which consists of more than 200 stakeholders and organizations collaborating on issues affecting the medical-cannabis industry. They will also accelerate progress toward shared and expanded research and patient access, serve ACCM's goals, and contribute to the industry’s long-term viability now anticipated through appropriate federal action.
“This MOU is significant because it recognizes ACCM’s leadership in medical-cannabis stewardship, and fosters a strong future for the U.S. medical-cannabis industry and overall support for the patient community through enhanced access,” says Jeff Kanter, ACCM Members Service Leader. Mr. Kanter added, “We will explore mutually beneficial opportunities for patients of all communities to gain benefits from federal changes, aligning resources, including research access and expanded data.”

The informative meetings included dozens of leaders working toward the industry’s collective 2021 industry stewardship and advocacy goals:

-Forum featuring representatives from The Zermatt Medical Institute and The American Society of Cannabis Medicine reviewed essential objectives for appropriate federal changes moving forward.

-Discussion by Dale Paulson, PhD, a research scientist and index specialist, reviewed metrics for the new MedCann Index, which will evaluate and score all state medical cannabis programs and provide guidance for the industry.

-Representatives from the Healthcare Freedom Hub, EM2P2, Inc., Dragonfly Medical, the Member First Health Network, and Association Health Partners shared insights about moving the industry toward traditional healthcare models enabled under reasonable federal legislation.

“The time has come to fully move the needle in the medical-cannabis space. Real clinical research and proper legislation is long overdue. My team’s focus is the translation of real science merged into current medical practices for the implementation of cannabis into patient care,” said Annabelle Manalo-Morgan PhD, Zermatt Medical Institute Research Committee Chairperson, ASCM Board of Regents Member, and ACCM Clinical Research Committee Co- Chair. “ACCM has assembled the blue-ribbon team to help carry the industry to the next level. Cannabis needs to now get to a point where leaders and the people can trust it. Our approach will revolutionize the cannabis industry and normalize the administration of cannabinoid products by the medical space. We are so pleased to be a part of this MOU; it really signifies the commitment.”

Gennaro Luce, CEO of EM2P2, Inc./CannaLnx and ACCM Medical Industry Committee Co- Chair, added “Over the last few years ACCM has proven to be a very powerful working group that understands the significant medical ramifications of the medical-cannabis industry for options in patient-centric care. “As an industry-leading company originating in traditional medicine, EM2P2/CannaLnx is pleased to strengthen its involvement with such a prestigious group, and to be a signatory of the new professional Alliance.”

“As a pioneer in the medical-cannabis world, it is very exciting to see the progress made toward increasing access and clearing the way to facilitate research and development in this dynamic industry,” said Noemi Perez, CEO of GreenBookAcademy, Director for NACDT and ACCM Education Committee Co-Chair. “From its inception, ACCM has been a valuable resource for legislators as well as multiple legislative initiatives, continually pushing high standards on education and professionalism in multiple states”

“With more than 45 years of political and legislative experience, it is a breath of fresh air to be working with a group so focused on real medical solutions through federal and state legislative initiatives,” said Mark Block, CEO of Mother Nature's Trading Company, ACCM Legislative Committee Co-Chair, and ACCM CBD Industry Liaison Committee Co-Chair. “As the only national group focused exclusively on medical cannabis on Capitol Hill, they have really taken the reins over the last few years, and this new initiative further solidifies their commitment of driving professionalism for the industry they represent.”

“Working with ACCM over the last year has opened my eyes to their depth and understanding of the entire industry ,” said Matt Hawkes, CEO of Global Product Makers, Inc .and ACCM Associate Committee Member “As a company that has worked on multiple FDA studies as a medical product innovator, this Alliance is heads above anything else in medical cannabis, we are glad to be participating.”

ACCM represents all segments of America’s medical-cannabis industry, which supports millions of U.S. jobs and is backed by a growing grassroots movement including millions of industry beneficiaries. Our industry members produce, process, and distribute medical cannabis through state-licensed programs and the companies supporting them. Additionally, our members come from the healthcare industry, including physicians, researchers, health and wellness providers, insurance companies and systems, and advocacy groups representing medical-cannabis patients. They participate in ACCM's 14 standing area-centric committees. ACCM was started in 2016 as a Capitol Hill working group and has developed into the voice of the American medical cannabis industry.

For information, please reach out to the American Council of Cannabis Medicine at

202-349- 9650, ext. 800, or visit www.accmforum.org.

Quote References:

Jeffery Block, M.D.

-ACCM Medical Community Committee Co-Chair

-ASCM Board of Regents Member

-Nurturing Nature

www.nurturingnature.com

Mark Block

-ACCM Legislative Committee Co-Chair

-Mother Natures Trading Company

www.mntc.shop